The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer
Open accessAbstract
This study evaluates the degree and relevance of persisting ototoxicity after cisplatin-based standard-dose chemotherapy for testicular cancer, with emphasis on identification of potential factors for an increased risk of this late sequel. Hearing thresholds of 86 patients with a median age of 31 years (range 21-53 years) and a median follow-up time of 58 months (range 15-159 months) were assessed by conventional pure-tone audiometry. Interviews were conducted evaluating the patients' history with special regard to audiological risk factors, as well as circumstances of ototoxic symptoms. Details concerning treatment and patient variables were extracted retrospectively from the patients' charts. An additional screening programme assessed current body functions, blood parameters and other late toxicities. Symptomatic ototoxicity persisted in 20% of patients (59% tinnitus, 18% hearing loss, 23% both), while 10% had experienced completely reversible ototoxic symptoms for a duration of 1-18 months after treatment. Symptoms were bilateral in 81% of patients. Hearing thresholds were compatible with cisplatin-induced hearing loss in 42% of audiograms performed. Subjective (history) and objective (audiogram) findings were not always consistent. The following statistically significant risk factors for ototoxicity were established: high cumulative dose of cisplatin (P < 0.0001); history of noise exposure (P = 0.006). Additionally, high doses of vincristine (P = 0.001) seemed to result in reversible ototoxic symptoms. No other independent risk factors were identified. In conclusion, persisting ototoxicity represents a clinical sequel for approximately 20% of testicular cancer patients treated at standard dose but may affect more than 50% of patients receiving cumulative doses of cisplatin > 400 mg m(-2). Previous noise exposure may also result in a threefold increased risk for cisplatin ototoxicity. Future studies should use these risk factors as important stratification criteria for trials aiming at the evaluation and prevention of cisplatin-induced ototoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bosl, G. J., & Motzer, R. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370406 · Cited by 891
Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., & Glick, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2101 · Cited by 463
Mechanism of Cisplatin Ototoxicity: Antioxidant System
Ravi, R., Somani, S. M., & Rybak, L. P. (1995) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1995.tb00167.x · Cited by 319
Evaluation of long-term toxicity after chemotherapy for testicular cancer.
Bokemeyer, C., Berger, C. C., Kuczyk, M. A., & Schmoll, H. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2923 · Cited by 268
Self-citationOtotoxicity of the Anticancer Drug Cisplatin:An Experimental Study
Nakai, Y., Konishi, K., Chang, K. C., Ohashi, K., Morisaki, N., Minowa, Y., & Morimoto, A. (1982) · Acta Oto-Laryngologica · doi:10.3109/00016488209130876 · Cited by 165
Ototoxicity of Chemotherapeutic Agents
Schweitzer, V. G. (1993) · Otolaryngologic Clinics of North America · doi:10.1016/s0030-6665(20)30766-0 · Cited by 154
Helson, L., Okonkwo, E., Anton, L., & Cvitkovic, E. (1978) · Clinical Toxicology · doi:10.3109/15563657808988252 · Cited by 151
Long-term effects of chemotherapy in patients with testicular cancer.
Osanto, S., Bukman, A., van Hoek, F., Sterk, P. J., de Laat, J. A. P. M., & Hermans, J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.574 · Cited by 143
Stoter, G., Koopman, A., Vendrik, C. P. J., Struyvenberg, A., Sleyfer, D. T., Willemse, P. H. B., Koops, H. S., van Oosterom, A. T., Huinink, W. W. T. B., & Pinedo, H. M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1099 · Cited by 118
Interaction of cisplatin and noise on the peripheral auditory system
Gratton, M. A., Salvi, R., Kamen, B. A., & Saunders, S. S. (1990) · Hearing Research · doi:10.1016/0378-5955(90)90046-r · Cited by 95
Long-term toxicity of chemotherapy for testicular cancer – the cost of cure
Stuart, N., Woodroffe, C. M., Grundy, R. G., & Cullen, M. H. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.106 · Cited by 94
Boyer, M. J., Raghavan, D., Harris, P. J., Lietch, J., Bleasel, A., Walsh, J. C., Anderson, S., & Tsang, C. S. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.21 · Cited by 91
Ototoxicity of the Anticancer Drug Cisplatin
Konishi, K., Nakai, Y., Chang, K., et al. (1981) · Ear research Japan · doi:10.11289/otoljpn1981.12.94 · Cited by 66
Renal and metabolic toxicities of cancer chemotherapy.
Schilsky, R. L. (1982) · PubMed · Cited by 57
Ototoxicity Resulting From Combined Administration of Cisplatin and Gentamicin
Riggs, L. C., Brummett, R. E., Guitjens, S. K., et al. (1996) · The Laryngoscope · doi:10.1097/00005537-199604000-00003 · Cited by 26
Enhanced ototoxicity of gentamicin and salicylate caused by Mg deficiency and Zn deficiency
Günther, T., Rebentisch, E., Vormann, J., König, M., & Ising, H. (1988) · Biological Trace Element Research · doi:10.1007/bf02795332 · Cited by 21
[Tinnitus in the diagnosis and prognosis of ototoxicity].
Doménech, J., Carulla, M., & Traserra, J. (1990) · PubMed · Cited by 2
Cited by
Drug-induced oxidative stress and toxicity
Deavall, D. G., Martin, E. A., Horner, J. M., & Roberts, R. (2012) · Journal of Toxicology · doi:10.1155/2012/645460 · Cited by 689
An integrated view of cisplatin-induced nephrotoxicity and ototoxicity
Karasawa, T., & Steyger, P. S. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.06.012 · Cited by 475
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies
Rybak, L. P., Mukherjea, D., Jajoo, S., & Ramkumar, V. (2009) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.219.177 · Cited by 372
Medical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 370
Metadata
- Authors
- Bokemeyer, C., Berger, C., Hartmann, J., Kollmannsberger, C., Schmoll, H., Kuczyk, M., & Kanz, L.
- Venue
- British Journal of Cancer
- Published
- 1998-04
- Volume
- 77
- Issue
- 8
- Pages
- 1355-1362
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2059998155
- Cited by
- 339
- References
- 17
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.